Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
75,239 questions in 5,342 reviews
current versionsNo studies 15,213 · 20.2%Ungraded 10,323 · 13.7%Very low 17,528 · 23.3%Low 17,951 · 23.9%Moderate 11,190 · 14.9%High 3,034 · 4%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Zinc vs placebo Mental Development Index BSID II. Scale from: 0 to 100 · infants and children Zinc supplementation for mental and motor development in children (2012) · Cochrane | no estimate extracted | 8 studies · 2134 participants | Moderate |
Zinc vs placebo Psychomotor Development Index BSID II. Scale from: 0 to 100 · infants and children Zinc supplementation for mental and motor development in children (2012) · Cochrane | no estimate extracted | 8 studies · 2134 participants | Moderate |
Zinc vs placebo Cognition scores · infants and children Zinc supplementation for mental and motor development in children (2012) · Cochrane | no estimate extracted | NR | No studies |
Zinc vs placebo Intelligence quotient · infants and children Zinc supplementation for mental and motor development in children (2012) · Cochrane | no estimate extracted | NR | No studies |
Zinc vs placebo Adverse effects · infants and children Zinc supplementation for mental and motor development in children (2012) · Cochrane | no estimate extracted | NR | No studies |
Rheum officinale vs no treatment Incidence of ESKD Analysis method, calculated by regression analysis: 1/SCr versus time. · Patients with chronic kidney disease Rheum officinale (a traditional Chinese medicine) for chronic kidney disease (2012) · Cochrane | RR 0.53 [0.28, 1] | 2 studies · 124 participants | Low |
Rheum officinale vs captopril Full time working capacity Unclear quality of life scale · Patients chronic kidney disease Rheum officinale (a traditional Chinese medicine) for chronic kidney disease (2012) · Cochrane | RR 1.02 [0.39, 2.71] | 1 study · 20 participants | Low |
Rheum officinale vs captopril Part‐time working capacity Unclear quality of life scale · Patients chronic kidney disease Rheum officinale (a traditional Chinese medicine) for chronic kidney disease (2012) · Cochrane | RR 1.64 [0.38, 6.98] | 1 study · 20 participants | Low |
Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical Overall survival (median 2 years) · patients with chronic lymphocytic leukaemia Alemtuzumab for patients with chronic lymphocytic leukaemia (2012) · Cochrane | HR 0.65 [0.45, 0.94] | 1 study · 335 participants | Moderate |
Anti‐leukaemic therapy with alemtuzumab vs anti‐leukaemic therapy without alemtuzumab (anti‐leukaemic therapy not identical Treament related mortality · patients with chronic lymphocytic leukaemia Alemtuzumab for patients with chronic lymphocytic leukaemia (2012) · Cochrane | RR 3.2 [0.66, 15.5] | 2 studies · 177 participants | Low |
Anti‐leukaemic therapy with alemtuzumab vs anti‐leukaemic therapy without alemtuzumab (anti‐leukaemic therapy not identical Complete response rate · patients with chronic lymphocytic leukaemia Alemtuzumab for patients with chronic lymphocytic leukaemia (2012) · Cochrane | RR 0.85 [0.67, 1.08] | 2 studies · 170 participants | Moderate |
Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical Progression free survival (median 2 years) · patients with chronic lymphocytic leukaemia Alemtuzumab for patients with chronic lymphocytic leukaemia (2012) · Cochrane | HR 0.61 [0.47, 0.81] | 2 studies · 356 participants | Low |
Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical Treatment related mortality · patients with chronic lymphocytic leukaemia Alemtuzumab for patients with chronic lymphocytic leukaemia (2012) · Cochrane | RR 0.57 [0.17, 1.9] | 2 studies · 356 participants | Moderate |
Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical Cytomegalovirus reactivation · patients with chronic lymphocytic leukaemia Alemtuzumab for patients with chronic lymphocytic leukaemia (2012) · Cochrane | RR 10.52 [1.42, 77.68] | 2 studies · 350 participants | High |
Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical Complete response rate · patients with chronic lymphocytic leukaemia Alemtuzumab for patients with chronic lymphocytic leukaemia (2012) · Cochrane | RR 2.61 [1.26, 5.42] | 2 studies · 356 participants | Low |
Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical Infections (all grades) · patients with chronic lymphocytic leukaemia Alemtuzumab for patients with chronic lymphocytic leukaemia (2012) · Cochrane | RR 1.32 [1.01, 1.74] | 2 studies · 356 participants | Low |
Anti‐leukaemic therapy plus alemtuzumab vs anti‐leukaemic therapy alone (anti‐leukaemic therapy identical Serious adverse events · patients with chronic lymphocytic leukaemia Alemtuzumab for patients with chronic lymphocytic leukaemia (2012) · Cochrane | RR 1.34 [0.95, 1.89] | 2 studies · 350 participants | Moderate |
Anti‐leukaemic therapy with alemtuzumab vs anti‐leukaemic therapy without alemtuzumab (anti‐leukaemic therapy not identical Overall survival not reported · patients with chronic lymphocytic leukaemia Alemtuzumab for patients with chronic lymphocytic leukaemia (2012) · Cochrane | no estimate extracted | NR | No studies |
Anti‐leukaemic therapy with alemtuzumab vs anti‐leukaemic therapy without alemtuzumab (anti‐leukaemic therapy not identical Progression free survival not reported · patients with chronic lymphocytic leukaemia Alemtuzumab for patients with chronic lymphocytic leukaemia (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR OS (at 3 years) · newly diagnosed or relapsed patients with CLL Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia (2012) · Cochrane | HR 0.78 [0.62, 0.98] | 3 studies · 1421 participants | High |
Intervention NR TRM · newly diagnosed or relapsed patients with CLL Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia (2012) · Cochrane | RR 0.31 [0.06, 1.51] | 2 studies · 177 participants | Low |
Intervention NR PFS (at 3 years) · newly diagnosed or relapsed patients with CLL Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia (2012) · Cochrane | HR 0.64 [0.55, 0.74] | 3 studies · 1421 participants | Moderate |
Intervention NR TRM · newly diagnosed or relapsed patients with CLL Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia (2012) · Cochrane | RR 1.19 [0.7, 2.01] | 3 studies · 1415 participants | Moderate |
Intervention NR SAEs ‐ overall analysis · newly diagnosed or relapsed patients with CLL Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia (2012) · Cochrane | RR 1.05 [0.89, 1.23] | 2 studies · 598 participants | Low |
Intervention NR Grade 3/4 AEs ‐ overall analysis · newly diagnosed or relapsed patients with CLL Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia (2012) · Cochrane | RR 1.15 [1.08, 1.23] | 3 studies · 1398 participants | Moderate |
Intervention NR OS not reported · newly diagnosed or relapsed patients with CLL Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR PFS not reported · newly diagnosed or relapsed patients with CLL Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia (2012) · Cochrane | no estimate extracted | 0 participants | Ungraded |
Intervention NR Time to next treatment · newly diagnosed or relapsed patients with CLL Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia (2012) · Cochrane | no estimate extracted | 0 participants | Ungraded |
Intervention NR CRR · newly diagnosed or relapsed patients with CLL Rituximab, ofatumumab and other monoclonal anti‐CD20 antibodies for chronic lymphocytic leukaemia (2012) · Cochrane | RR 1.18 [0.93, 1.49] | 2 studies · 170 participants | Moderate |
Intervention NR Diabetic complications · patients with type 1 diabetes mellitus Continuous glucose monitoring systems for type 1 diabetes mellitus (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Ketoacidosis · patients with type 1 diabetes mellitus Continuous glucose monitoring systems for type 1 diabetes mellitus (2012) · Cochrane | RR 0.85 [0.32, 2.26] | 5 studies · 689 participants | Low |
Intervention NR Quality of life ‐ Physical health domain SF‐12 · patients with type 1 diabetes mellitus Continuous glucose monitoring systems for type 1 diabetes mellitus (2012) · Cochrane | no estimate extracted | 1 study · 226 participants | Very low |
Intervention NR Quality of life ‐ Mental health domain SF‐12 · patients with type 1 diabetes mellitus Continuous glucose monitoring systems for type 1 diabetes mellitus (2012) · Cochrane | no estimate extracted | 1 study · 226 participants | Very low |
Intervention NR Quality of life ‐ Parents SF‐12 · patients with type 1 diabetes mellitus Continuous glucose monitoring systems for type 1 diabetes mellitus (2012) · Cochrane | no estimate extracted | 1 study · 226 participants | Very low |
Intervention NR Change in HbA1c (%) · patients with type 1 diabetes mellitus Continuous glucose monitoring systems for type 1 diabetes mellitus (2012) · Cochrane | no estimate extracted | 6 studies · 963 participants | Moderate |
Intervention NR Severe hypoglycaemia · patients with type 1 diabetes mellitus Continuous glucose monitoring systems for type 1 diabetes mellitus (2012) · Cochrane | RR 3.26 [0.38, 27.82] | 1 study · 78 participants | Very low |
Intervention NR Ketoacidosis · patients with type 1 diabetes mellitus Continuous glucose monitoring systems for type 1 diabetes mellitus (2012) · Cochrane | RR 2.45 [0.1, 58.45] | 1 study · 78 participants | Very low |
Intervention NR Quality of life ‐ Various features · patients with type 1 diabetes mellitus Continuous glucose monitoring systems for type 1 diabetes mellitus (2012) · Cochrane | no estimate extracted | 5 studies · 412 participants | Ungraded |
Intervention NR Quality of life ‐ Physical health domain SF‐36 Short form · patients with type 1 diabetes mellitus Continuous glucose monitoring systems for type 1 diabetes mellitus (2012) · Cochrane | no estimate extracted | 1 study · 75 participants | Very low |
Intervention NR Quality of life ‐ Mental health domain SF‐36 Short form · patients with type 1 diabetes mellitus Continuous glucose monitoring systems for type 1 diabetes mellitus (2012) · Cochrane | no estimate extracted | 1 study · 75 participants | Very low |
Intervention NR Change in HbA1c (%) · patients with type 1 diabetes mellitus Continuous glucose monitoring systems for type 1 diabetes mellitus (2012) · Cochrane | no estimate extracted | 2 studies · 562 participants | Moderate |
Intervention NR Diabetic complications · patients with type 1 diabetes mellitus Continuous glucose monitoring systems for type 1 diabetes mellitus (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Severe hypoglycaemia · patients with type 1 diabetes mellitus Continuous glucose monitoring systems for type 1 diabetes mellitus (2012) · Cochrane | RR 1.05 [0.63, 1.77] | 5 studies · 689 participants | Low |
Intervention NR Total Successful Intubation Rate · patients with Transparent Cap Colonoscopy versus Standard Colonoscopy to Improve Caecal Intubation (2012) · Cochrane | OR 1.36 [0.95, 1.93] | 12 studies · 5932 participants | Moderate |
Intervention NR All cause mortality ‐ 30 days · Prevention and treatment of infectious complications in patients with acute myelogenous leukemia Colony‐stimulating factors for prevention and treatment of infectious complications in patients with acute… (2012) · Cochrane | RR 0.97 [0.8, 1.18] | 11 studies · 3319 participants | Low |
Intervention NR Bacteremia · Prevention and treatment of infectious complications in patientswith acute myelogenous leukemia Colony‐stimulating factors for prevention and treatment of infectious complications in patients with acute… (2012) · Cochrane | RR 0.96 [0.82, 1.12] | 7 studies · 1638 participants | Moderate |
Intervention NR Very wide CI · Prevention and treatment of infectious complications in patientswith acute myelogenous leukemia Colony‐stimulating factors for prevention and treatment of infectious complications in patients with acute… (2012) · Cochrane | no estimate extracted | 1 participants | Ungraded |
Intervention NR Invasive fungal infection · Prevention and treatment of infectious complications in patientswith acute myelogenous leukemia Colony‐stimulating factors for prevention and treatment of infectious complications in patients with acute… (2012) · Cochrane | RR 1.4 [0.9, 2.19] | 4 studies · 929 participants | Low |
Intervention NR Episodes of febrile neutropenia · patients with prevention and treatment of infectious complications in patients with acute myelogenous leukemia Colony‐stimulating factors for prevention and treatment of infectious complications in patients with acute… (2012) · Cochrane | RR 0.98 [0.94, 1.03] | 9 studies · 2140 participants | Moderate |
Intervention NR Adverse events requiring discontinuation of CSFs · Prevention and treatment of infectious complications in patients with acute myelogenous leukemia Colony‐stimulating factors for prevention and treatment of infectious complications in patients with acute… (2012) · Cochrane | RR 1.33 [1, 1.76] | 4 studies · 770 participants | Very low |